JP2015517305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517305A5 JP2015517305A5 JP2015510818A JP2015510818A JP2015517305A5 JP 2015517305 A5 JP2015517305 A5 JP 2015517305A5 JP 2015510818 A JP2015510818 A JP 2015510818A JP 2015510818 A JP2015510818 A JP 2015510818A JP 2015517305 A5 JP2015517305 A5 JP 2015517305A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fxia
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102100030563 Coagulation factor XI Human genes 0.000 claims 1
- 108010074864 Factor XI Proteins 0.000 claims 1
- 108010080805 Factor XIa Proteins 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 101710161089 Coagulation factor XI Proteins 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000004091 panning Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 206010014009 Ear haemorrhage Diseases 0.000 description 6
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 102100023472 P-selectin Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 101001062768 Homo sapiens Coagulation factor XI Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- HRYITGOEDRTTLM-FRSCJGFNSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HRYITGOEDRTTLM-FRSCJGFNSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167438.6 | 2012-05-10 | ||
| EP12167438 | 2012-05-10 | ||
| EP12181697.9 | 2012-08-24 | ||
| EP12181697 | 2012-08-24 | ||
| EP13150361 | 2013-01-07 | ||
| EP13150361.7 | 2013-01-07 | ||
| US201361817675P | 2013-04-30 | 2013-04-30 | |
| US61/817,675 | 2013-04-30 | ||
| PCT/EP2013/059618 WO2013167669A1 (en) | 2012-05-10 | 2013-05-08 | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018106275A Division JP2018148920A (ja) | 2012-05-10 | 2018-06-01 | 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517305A JP2015517305A (ja) | 2015-06-22 |
| JP2015517305A5 true JP2015517305A5 (enExample) | 2016-06-23 |
| JP6348900B2 JP6348900B2 (ja) | 2018-06-27 |
Family
ID=49550177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510818A Active JP6348900B2 (ja) | 2012-05-10 | 2013-05-08 | 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 |
| JP2018106275A Pending JP2018148920A (ja) | 2012-05-10 | 2018-06-01 | 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018106275A Pending JP2018148920A (ja) | 2012-05-10 | 2018-06-01 | 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9783614B2 (enExample) |
| EP (2) | EP2847228B1 (enExample) |
| JP (2) | JP6348900B2 (enExample) |
| KR (1) | KR102060376B1 (enExample) |
| CN (1) | CN104684932B (enExample) |
| AR (1) | AR091024A1 (enExample) |
| AU (2) | AU2013258043B2 (enExample) |
| BR (1) | BR112014027952B1 (enExample) |
| CA (1) | CA2872926C (enExample) |
| DK (1) | DK2847228T3 (enExample) |
| ES (1) | ES2698950T3 (enExample) |
| HR (1) | HRP20181680T1 (enExample) |
| HU (1) | HUE040580T2 (enExample) |
| IL (1) | IL235238B (enExample) |
| LT (1) | LT2847228T (enExample) |
| MX (1) | MX362454B (enExample) |
| NZ (1) | NZ701121A (enExample) |
| PL (1) | PL2847228T3 (enExample) |
| RS (1) | RS57889B1 (enExample) |
| SG (2) | SG11201406719UA (enExample) |
| SI (1) | SI2847228T1 (enExample) |
| TW (2) | TWI644925B (enExample) |
| WO (1) | WO2013167669A1 (enExample) |
| ZA (1) | ZA201407784B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008326348B2 (en) | 2007-11-21 | 2014-01-30 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
| AU2009335643B2 (en) | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| HRP20170784T8 (hr) | 2011-10-14 | 2018-05-18 | Bristol-Myers Squibb Company | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| SI2847228T1 (sl) | 2012-05-10 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe |
| HRP20180465T1 (hr) | 2012-10-12 | 2018-05-04 | Bristol-Myers Squibb Company | Kristalni oblici inhibitora faktora xia |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| UY35971A (es) | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
| SG10201805646WA (en) | 2014-08-07 | 2018-08-30 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3240570B1 (en) | 2015-01-02 | 2025-09-24 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor xii |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| EA201890340A1 (ru) | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | Моноклональное антитело-ингибитор фактора xiia |
| EP3325010B1 (en) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antibodies to coagulation factor xia and uses thereof |
| AR107505A1 (es) * | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
| US11059905B2 (en) | 2016-03-23 | 2021-07-13 | Prothix B.V. | Monoclonal antibodies against the active site of factor XI and uses thereof |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| KR102218714B1 (ko) | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | 항응고 인자 xi 항체 |
| DK3515947T3 (da) * | 2016-09-20 | 2024-07-29 | Aronora Inc | Hidtil ukendte antistoffer mod faktor XI og anvendelser deraf |
| EP3535390A4 (en) * | 2016-11-02 | 2020-11-25 | Inc. Aronora | COMBINATION OF THROMBIN E-WE ANALOGUE AND FIBRINOLYTIC |
| AU2017383232B2 (en) * | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| US20200231701A1 (en) * | 2016-12-23 | 2020-07-23 | Novartis Ag | Methods of treatment with anti-factor xi/xia antibodies |
| BR112019014785A2 (pt) * | 2017-01-19 | 2020-05-12 | Bayer Pharma Aktiengesellschaft | Nova formulação estável para anticorpos fxia |
| WO2020029179A1 (en) * | 2018-08-09 | 2020-02-13 | Shanghai Benemae Pharmaceutical Corporation | Anti-factor xi antibodies |
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| WO2019102353A1 (en) | 2017-11-22 | 2019-05-31 | Novartis Ag | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| JP2021529800A (ja) * | 2018-07-05 | 2021-11-04 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ＦＸＩａ抗体のための新規な安定した高濃度製剤 |
| PE20211399A1 (es) * | 2018-08-01 | 2021-07-27 | Novo Nordisk As | Anticuerpos procoagulantes mejorados |
| CN120433850A (zh) | 2018-08-07 | 2025-08-05 | 日本电信电话株式会社 | 光传输系统和传输模式选择方法 |
| CN113348000A (zh) * | 2018-09-17 | 2021-09-03 | 德克萨斯大学体系董事会 | 用于治疗骨损伤的组合物和方法 |
| WO2020089380A1 (en) | 2018-10-31 | 2020-05-07 | Bayer Aktiengesellschaft | REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES |
| EP3914624A4 (en) * | 2019-01-21 | 2022-10-19 | Aronora, Inc. | NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES |
| CN113474374B (zh) | 2019-04-16 | 2025-05-02 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| CN110423278B (zh) | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| TWI882142B (zh) * | 2020-07-02 | 2025-05-01 | 大陸商北京拓界生物醫藥科技有限公司 | 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途 |
| WO2024141099A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| CN119454938B (zh) * | 2024-11-15 | 2025-07-25 | 广州骐骥生物科技有限公司 | 一种枸橼酸透析浓缩液及其制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| DE4319041A1 (de) | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US20030235587A1 (en) | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| ES2325045T3 (es) | 1996-10-14 | 2009-08-24 | Bayer Healthcare Ag | Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares. |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| WO2000007626A1 (en) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| DE19920352A1 (de) | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US20080219998A1 (en) | 2001-12-07 | 2008-09-11 | Andras Gruber | Anti-Thrombotic Agents |
| US7270976B2 (en) | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US20080138837A1 (en) | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
| US7279513B2 (en) | 2004-11-19 | 2007-10-09 | Nalco Company | Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion |
| DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
| DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
| DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| EP3018144A1 (en) | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| CA2685015A1 (en) | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| US8574849B2 (en) | 2007-10-03 | 2013-11-05 | The University Of Vermont And State Agriculture College | Methods of detection of factor XIa and tissue factor |
| AU2008326348B2 (en) * | 2007-11-21 | 2014-01-30 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
| HUE041556T2 (hu) * | 2008-06-19 | 2019-05-28 | Prothix Bv | XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| AU2009335643B2 (en) * | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| KR20140019004A (ko) | 2010-05-27 | 2014-02-13 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| EP2585055A1 (de) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
| CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| US20140171434A1 (en) | 2011-01-11 | 2014-06-19 | Bayer Pharma Aktiengessellschaft | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| CN103619845B (zh) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | 氟烷基取代的吡唑并吡啶及其用途 |
| CA2844730A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| JP6054967B2 (ja) | 2011-09-02 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換アネレート化ピリミジンおよびその使用 |
| SI2847228T1 (sl) * | 2012-05-10 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe |
-
2013
- 2013-05-08 SI SI201331209T patent/SI2847228T1/sl unknown
- 2013-05-08 PL PL13721746T patent/PL2847228T3/pl unknown
- 2013-05-08 SG SG11201406719UA patent/SG11201406719UA/en unknown
- 2013-05-08 JP JP2015510818A patent/JP6348900B2/ja active Active
- 2013-05-08 RS RS20181219A patent/RS57889B1/sr unknown
- 2013-05-08 LT LTEP13721746.9T patent/LT2847228T/lt unknown
- 2013-05-08 AU AU2013258043A patent/AU2013258043B2/en not_active Ceased
- 2013-05-08 NZ NZ701121A patent/NZ701121A/en not_active IP Right Cessation
- 2013-05-08 ES ES13721746T patent/ES2698950T3/es active Active
- 2013-05-08 US US14/400,281 patent/US9783614B2/en active Active
- 2013-05-08 HR HRP20181680TT patent/HRP20181680T1/hr unknown
- 2013-05-08 EP EP13721746.9A patent/EP2847228B1/en active Active
- 2013-05-08 BR BR112014027952-7A patent/BR112014027952B1/pt active IP Right Grant
- 2013-05-08 SG SG10201609322QA patent/SG10201609322QA/en unknown
- 2013-05-08 KR KR1020147034253A patent/KR102060376B1/ko not_active Expired - Fee Related
- 2013-05-08 DK DK13721746.9T patent/DK2847228T3/en active
- 2013-05-08 CN CN201380037161.1A patent/CN104684932B/zh active Active
- 2013-05-08 EP EP18176293.1A patent/EP3404045A1/en not_active Withdrawn
- 2013-05-08 CA CA2872926A patent/CA2872926C/en active Active
- 2013-05-08 MX MX2014013568A patent/MX362454B/es active IP Right Grant
- 2013-05-08 HU HUE13721746A patent/HUE040580T2/hu unknown
- 2013-05-08 WO PCT/EP2013/059618 patent/WO2013167669A1/en not_active Ceased
- 2013-05-09 TW TW106143305A patent/TWI644925B/zh not_active IP Right Cessation
- 2013-05-09 TW TW102116466A patent/TWI631140B/zh not_active IP Right Cessation
- 2013-05-10 AR ARP130101638A patent/AR091024A1/es not_active Application Discontinuation
-
2014
- 2014-10-21 IL IL235238A patent/IL235238B/en active IP Right Grant
- 2014-10-24 ZA ZA2014/07784A patent/ZA201407784B/en unknown
-
2017
- 2017-08-30 US US15/691,731 patent/US10221247B2/en active Active
- 2017-08-30 US US15/691,736 patent/US10040866B2/en active Active
-
2018
- 2018-02-06 AU AU2018200850A patent/AU2018200850C1/en not_active Ceased
- 2018-06-01 JP JP2018106275A patent/JP2018148920A/ja active Pending
-
2019
- 2019-03-04 US US16/292,196 patent/US11046783B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517305A5 (enExample) | ||
| Jin et al. | Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches | |
| Haemmerle et al. | The platelet lifeline to cancer: challenges and opportunities | |
| Miller et al. | Pulmonary complications of sickle cell disease | |
| Seth et al. | Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model | |
| Gailani et al. | Targeting factor XI and factor XIa to prevent thrombosis | |
| Daniels et al. | Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results | |
| JP2023040077A (ja) | Ｔ制御性細胞の増殖または枯渇方法 | |
| Tati et al. | Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy | |
| Goschnick et al. | Impaired “outside-in” integrin αIIbβ3 signaling and thrombus stability in TSSC6-deficient mice | |
| Hally et al. | Platelet Toll-like receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction | |
| JP2015534949A (ja) | 免疫応答の増強 | |
| David et al. | Factor XIa–specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis | |
| Jensen et al. | The haematocrit–an important factor causing impaired haemostasis in patients with cyanotic congenital heart disease | |
| Winterberg et al. | T cells play a causal role in diastolic dysfunction during uremic cardiomyopathy | |
| Curnow et al. | Why do patients bleed? | |
| DeLyria et al. | Fatal cryocrystalglobulinemia with intravascular and renal tubular crystalline deposits | |
| Pan et al. | GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI | |
| JP2014529606A5 (enExample) | ||
| Zhu et al. | Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients | |
| Pervaiz et al. | Pulmonary complications of sickle cell disease: a narrative clinical review | |
| Hant et al. | Pulmonary manifestations of scleroderma and mixed connective tissue disease | |
| Kohs et al. | Activation of coagulation FXI promotes endothelial inflammation and amplifies platelet activation in a nonhuman primate model of hyperlipidemia | |
| Bos et al. | Hemostatic complications in hepatobiliary surgery | |
| Mauriello et al. | Factor XI and Cancer: Physiopathological Linkage and Clinical Perspectives |